Skip to Main Content

“This is basically a game of corporate three-card monte.”

Likening Biogen to a sidewalk confidence game is how one particularly cynical portfolio manager of a biotech hedge fund responded when I asked for his take on Tuesday’s shocking biotech news: Biogen’s decision to resurrect its experimental Alzheimer’s drug aducanumab — and pursue regulatory approval — based on a new and more positive analysis from two large clinical trials previously thought to be negative.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!